18.222.10.49
dgid:
enl:
npi:0

-Advertisement-

-Advertisement-

Home Two-year results of RESTORE study highlight a mutation-agnostic gene therapy for retinitis pigmentosa

Retina

Two-year results of RESTORE study highlight a mutation-agnostic gene therapy for retinitis pigmentosa

Watch Now

By rd360stg

Study links maternal diabetes to severe retinopathy of prematurity risk

By rd360stg

PHOTON trial assesses aflibercept 8 mg for diabetic macular edema

By rd360stg

Modeling study observes extended durability of aflibercept 8 mg

By rd360stg

Regenxbio reports promising data on gene therapy for bilateral wet AMD

-Advertisement-

-Advertisement-

-Advertisement-

By rd360stg

Study highlights benefits of continuous glucose monitoring in slowing diabetic retinopathy progression

By rd360stg

PULSAR trial shows baseline metrics do not predict dosing schedules in nAMD treatment

By rd360stg

Shortened dosing intervals of aflibercept linked to improved visual acuity and retinal thickness

By rd360stg

Nutraceuticals remain important in the treatment of AMD and GA

-Advertisement-

-Advertisement-

-Advertisement-

By rd360stg

Global survey reveals trends in treatment for retinopathy of prematurity

By rd360stg

Online education increases ophthalmologists’ knowledge of emerging retinal disease treatments

By rd360stg

Weighing the risks of anti-VEGF use in pregnancy: new insights from pharmacokinetic and safety data

By rd360stg

Study finds significant predictors of persistent disease despite treatment with anti-VEGF agents

-Advertisement-

-Advertisement-

Videos

Two-year results of RESTORE study highlight a mutation-agnostic gene therapy for retinitis pigmentosa

07 Nov, 2024

Allen Ho, MD, Director of Retina Research at Wills Eye...

PHOTON trial assesses aflibercept 8 mg for diabetic macular edema

31 Oct, 2024

Modeling study observes extended durability of aflibercept 8 mg

30 Oct, 2024

-Advertisement-

Contact Info

Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809

+908-505-8899

[email protected]

Social Links

© 2024 Ophthalmology 360® is a trademark of International Healthcare Media, LLC. All rights Reserved

-Advertisement-

-Advertisement-